Medications for Hidradenitis Suppurativa
11 results
Abrilada (adalimumab-afzb)
(adalimumab-afzb)Pfizer Laboratories Div Pfizer Inc
Usage: ABRILADA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients 2 years and older.
Adalimumab (adalimumab)
(adalimumab)Golden State Medical Supply, Inc.
Usage: Adalimumab-fkjp is indicated for various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It reduces symptoms, inhibits structural damage progression, and improves physical function in affected patients.
Amjevita (adalimumab-atto)
(adalimumab-atto)Optum Health Solutions (Ireland) Limited
Usage: AMJEVITA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It can be used alone or with other therapies.
Amjevita (adalimumab-atto)
(adalimumab-atto)Amgen Inc
Usage: AMJEVITA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients. It can be used alone or with DMARDs.
Bimzelx (bimekizumab)
(bimekizumab)UCB, Inc.
Usage: BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who are candidates for systemic therapy or phototherapy.
Cosentyx (secukinumab)
(secukinumab)Novartis Pharmaceuticals Corporation
Usage: COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 2 years and older, ankylosing spondylitis in adults, non-radiographic axial spondyloarthritis in adults, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.
Cyltezo (adalimumab-adbm)
(adalimumab-adbm)Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, either alone or with other therapies.
Hadlima (adalimumab-bwwd)
(adalimumab-bwwd)Organon LLC
Usage: HADLIMA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients. It can be used alone or with other therapies.
Hulio (adalimumab-fkjp)
(adalimumab-fkjp)Mylan Specialty L.P.
Usage: HULIO is indicated for various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It aims to reduce symptoms, inhibit structural damage progression, and improve physical function in affected patients.
Humira (adalimumab)
(Adalimumab)AbbVie Inc.
Usage: HUMIRA is indicated for treating various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in patients aged 2 and older, either alone or with other therapies.